Astrocyte dysfunction may contribute to epileptogenesis and other neurological deficits in Tuberous Sclerosis Complex (TSC). In particular, decreased expression and function of astrocyte glutamate transporters have been implicated in causing elevated extracellular glutamate levels, neuronal death, and epilepsy in a mouse model of TSC (Tsc1 GFAP CKO mice), involving inactivation of the Tsc1 gene primarily in astrocytes. Here, we tested whether pharmacological induction of astrocyte glutamate transporter expression can prevent the neurological phenotype of Tsc1 GFAP CKO mice. Early treatment with ceftriaxone prior to the onset of epilepsy increased expression of astrocyte glutamate transporters, decreased extracellular glutamate levels, neuronal death, and seizure frequency, and improved survival in Tsc1 GFAP CKO mice. In contrast, late treatment with ceftriaxone after onset of epilepsy increased glutamate transporter expression, but had no effect on seizures. These results indicate that astrocyte glutamate transporters contribute to epileptogenesis in Tsc1 GFAP CKO mice and suggest novel therapeutic strategies for epilepsy in TSC directed at astrocytes.
Introduction
Tuberous Sclerosis Complex (TSC) is an autosomal dominant genetic disorder, resulting from mutation of either the TSC1 or TSC2 genes and involving tumor or hamartoma formation in multiple organs (Kwiatkowski, 2003; Crino et al., 2006; Holmes et al., 2007) . Neurological involvement, including epilepsy, cognitive deficits, and autism, often constitutes the most disabling symptoms of the disease. TSC is one of the most common genetic causes of epilepsy, and epilepsy in TSC is usually severe and intractable to currently available treatments. Although hamartomas in the brain (tubers) may serve as the foci for seizures in TSC, this is controversial, and the specific cellular and molecular mechanisms of epileptogenesis in TSC are incompletely understood (Wong, 2008) . Achieving a better understanding of the cellular and molecular basis of epileptogenesis should lead to more effective, rational therapies for epilepsy in TSC.
Recent studies in both human brain tissue and animal models of TSC suggest that astrocytes may play an important role in epileptogenesis and other neurological deficits in TSC (Uhlmann et al., 2002; Erbayat-Altay et al., 2007; Sosunov et al., 2008) . In one putative astrocyte-related mechanism, astrocytes could potentially promote epileptogenesis and neuronal dysfunction through abnormal regulation of extracellular and synaptic glutamate homeostasis. In support of this hypothesis, a knock-out mouse model of TSC (Tsc1 GFAP CKO mice) exhibits decreased expression and function of the astrocyte glutamate transporters, GLT-1 and GLAST, and an associated increase in extracellular glutamate levels and excitotoxic neuronal death (Wong et al., 2003; Zeng et al., 2007) . Abnormal glutamate homeostasis and neuronal death, in turn, may result in neurological deficits and promote neuronal hyperexcitability and seizures.
Targeting astrocytic mechanisms could represent a novel therapeutic approach for epilepsy and TSC. Beta-lactam antibiotics, such as ceftriaxone, and other pharmacological compounds have recently been reported to increase the expression of astrocyte glutamate transporters and correspondingly protect against glutamate excitotoxicity and neuronal injury (Rothstein et al., 2005; Ganel et al., 2006; Chu et al., 2007; Lipski et al., 2007) . Furthermore, modulation of astrocyte glutamate transporter expression improves survival and other neurological deficits in animal models of various neurological disorders, such as amyotrophic lateral sclerosis (Rothstein et al., 2005; Ganel et al., 2006; Lepore et al., 2008) . In the present study, we have tested whether a similar therapeutic approach of modulating astrocyte glutamate transporter expression is effective in countering 
